Diabetes in the Desert: What Do Patients Know about the Heat?

Nassar, Adrienne A.; Childs, Raymond D.; Boyle, Mary E.; Jameson, Kimberly A.; Fowke, Margaret; Waters, Ken R.; Hovan, Michael J.; Cook, Curtiss B.

doi:10.1177/193229681000400514

Cited by 15 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Due to impairment of thermoregulatory mechanism and alterations in cutaneous vasodilation, orthostatic responses in patients with T2DM in such weather could be compromised. [153] Higher emergency department visits and hospitalizations are observed during hot weather in diabetes patients. It was thought that the increased osmotic diuresis, triggered by SGLT2i theoretically, may worsen volume depletion in summer.…”

Section: Use In Special Populationsmentioning

confidence: 99%

Safe and pragmatic use of sodium–glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement

Kalra

Ghosh

Aamir

et al. 2017

Indian J Endocr Metab

View full text Add to dashboard Cite

Diabetes prevalence shows a continuous increasing trend in South Asia. Although well-established treatment modalities exist for type 2 diabetes mellitus (T2DM) management, they are limited by their side effect profile. Sodium–glucose co-transporter 2 inhibitors (SGLT2i) with their novel insulin-independent renal action provide improved glycemic control, supplemented by reduction in weight and blood pressure, and cardiovascular safety. Based on the clinical outcomes with SGLT2i in patients with T2DM, treatment strategies that make a “good clinical sense” are desirable. Considering the peculiar lifestyle, body types, dietary patterns (long duration religious fasts), and the hot climate of the South Asian population, a unanimous decision was taken to design specific, customized guidelines for T2DM treatment strategies in these regions. The panel met for a discussion three times so as to get a consensus for the guidelines, and only unanimous consensus was included. After careful consideration of the quality and strength of the available evidence, the executive summary of this consensus statement was developed based on the American Association of Clinical Endocrinologists/American College of Endocrinology protocol.

show abstract

Section: Use In Special Populationsmentioning

confidence: 99%

Safe and pragmatic use of sodium–glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement

Kalra

Ghosh

Aamir

et al. 2017

Indian J Endocr Metab

View full text Add to dashboard Cite

show abstract

“…3 Therefore, patients must find ways to adapt their disease management in warmer weather conditions to avoid potentially serious complications, adverse events (AEs) and hospitalisations. 1 Approximately, 90% of people with diabetes have type 2 diabetes mellitus (T2DM), which is characterised by hyperglycaemia, insulin resistance, and impaired beta-cell function. 3 Because uncontrolled hyperglycaemia can lead to microvascular and macrovascular complications of T2DM, 4 many organisations recommend that patients with T2DM implement lifestyle changes and/or begin treatment with antihyperglycaemic agents (AHAs) in order to lower their blood glucose levels.…”

mentioning

confidence: 99%

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates

John¹,

Cerdas²,

Violante³

et al. 2016

Int J Clin Pract

View full text Add to dashboard Cite

SummaryAimsPatients with type 2 diabetes mellitus (T2DM) have increased risk of adverse events (AEs; e.g. dehydration, hypoglycaemia) in hot weather. This analysis assessed the efficacy and safety of canagliflozin, a sodium glucose co‐transporter 2 (SGLT2) inhibitor, in patients with T2DM who live in hot climates.MethodsThis post hoc analysis evaluated patients with T2DM using pooled data from four 26‐week, placebo‐controlled studies (N=2,313) and data from a 104‐week, active‐controlled study (add‐on to metformin vs glimepiride; N=1,450). Changes in HbA1c, fasting plasma glucose (FPG), body weight and blood pressure (BP) were assessed in subsets of patients living in hot climates (pooled, placebo‐controlled studies, n=611; active‐controlled study, n=307) and those living in other climates (i.e. other climate subset; pooled, placebo‐controlled studies, n=1,702; active‐controlled study, n=1,143). Safety was assessed based on AE reports.ResultsCanagliflozin 100 and 300 mg lowered HbA1c, FPG, body weight and BP vs placebo over 26 weeks and glimepiride over 104 weeks in the hot climate subsets. Canagliflozin was generally well tolerated in the hot climate subsets, with a higher incidence of AEs related to the mechanism of SGLT2 inhibition (i.e. genital mycotic infections). Volume depletion–related AEs were low across groups.ConclusionCanagliflozin improved glycaemic control, lowered body weight and BP, and was generally well tolerated in patients with T2DM living in hot climates compared with placebo over 26 weeks or glimepiride over 104 weeks.Clinical Trials registration: ClinicalTrials.gov NCT01081834, NCT01106677, NCT01106625, NCT01106690, NCT00968812.

show abstract

“…More extreme temperatures, however, remain an important issue and focus for patient education. 15 The results of this study do, however, reinforce the need for advice to patients about regular catheter changes, particularly at 72 h.…”

Section: Skin Temperature and Insulin Pump Occlusion 1021mentioning

confidence: 50%

Influence of Local Skin Temperature and Choice of Insulin Analog on Catheter Occlusion Rates During Continuous Insulin Infusion: An Exploratory Study

Naik

Kerr

Begley

et al. 2012

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

show abstract

Diabetes in the Desert: What Do Patients Know about the Heat?

Cited by 15 publications

References 19 publications

Safe and pragmatic use of sodium–glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement

Safe and pragmatic use of sodium–glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates

Influence of Local Skin Temperature and Choice of Insulin Analog on Catheter Occlusion Rates During Continuous Insulin Infusion: An Exploratory Study

Contact Info

Product

Resources

About